| Title |
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150
|
|---|---|
| Published in |
British Journal of Cancer, October 2021
|
| DOI | 10.1038/s41416-021-01606-4 |
| Pubmed ID | |
| Authors |
Ashley M. Hopkins, Ganessan Kichenadasse, Ross A. McKinnon, Ahmad Y. Abuhelwa, Jessica M. Logan, Sarah Badaoui, Christos S. Karapetis, Andrew Rowland, Michael J. Sorich |
X Demographics
The data shown below were collected from the profiles of 37 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 3 | 8% |
| United States | 3 | 8% |
| France | 2 | 5% |
| Colombia | 1 | 3% |
| Spain | 1 | 3% |
| Italy | 1 | 3% |
| Unknown | 26 | 70% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 28 | 76% |
| Practitioners (doctors, other healthcare professionals) | 6 | 16% |
| Scientists | 3 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 47 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 8 | 17% |
| Researcher | 4 | 9% |
| Student > Ph. D. Student | 3 | 6% |
| Student > Postgraduate | 3 | 6% |
| Student > Doctoral Student | 2 | 4% |
| Other | 6 | 13% |
| Unknown | 21 | 45% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 11% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Computer Science | 2 | 4% |
| Immunology and Microbiology | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 22 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 117. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 January 2022.
All research outputs
#338,428
of 24,490,209 outputs
Outputs from British Journal of Cancer
#94
of 10,817 outputs
Outputs of similar age
#8,649
of 432,253 outputs
Outputs of similar age from British Journal of Cancer
#1
of 98 outputs
Altmetric has tracked 24,490,209 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,817 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 10.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 432,253 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.